Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectives

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 3, 2011, Pages 433-449

  El Saghir, Nagi S ^a   Tfayli, Arafat ^a   Hatoum, Hassan A ^a   Nachef, Zahi ^a   Dinh, Phuong ^b   Awada, Ahmad ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Anthracyclines; Anti angiogenesis; Anti EGFR; Anti ErbB2 targeted therapy; Anti RANKL; Aromatase inhibitors; Bisphosphonates; Chemotherapy; Endocrine treatment; Metastatic breast cancer; Palliation; PARP inhibitors; Survival; Taxanes

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANGIOGENESIS INHIBITOR; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; E 7289; ENDOTAG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERIBULIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOXETINE; FULVESTRANT; GEMCITABINE; IXABEPILONE; LETROZOLE; MEGESTROL ACETATE; MONOCLONAL ANTIBODY; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PAROXETINE; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG ANTAGONISM; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; HOT FLUSH; HUMAN; LIPOSOMAL DELIVERY; METASTASIS POTENTIAL; NEUROPATHY; OVERALL SURVIVAL; PREMENOPAUSE; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PALLIATIVE CARE; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; RANK LIGAND; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECURRENCE;

EID: 80655127884     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.01.010     Document Type: Review

References (133)

1. Sledge G.W., Neuberg D., Bernardo P., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003, 21(4 (February)):588-592.
2. Giordano S.H., Buzdar A.U., Smith T.L., Kau S.W., Yang Y., Hortobagyi G.N. Is breast cancer survival improving. Cancer 2004, 100:44-52.
3. Hortobagyi G.N. Can we cure limited metastatic breast cancer?. J Clin Oncol 2002, 20(3 (February)):620-623.
4. Lu W.L., Jansen L., Post W.J., Bonnema J., Van de Velde J.C., De Bock G.H. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 2009, 114(3 (April)):403-412.
5. Singletary S.E., Walsh G., Vauthey J.N., et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 2003, 8(3):241-251.
6. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14:2738-2746.
7. De Cremoux P., Grandin L., Dieras V., et al. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Res 2009, 29(5 (May)):1475-1482.
8. Hayes D.F. Prognostic and predictive factors revisited. Breast 2005, 14(6 (December)):493-499. [Epub 2005 October 18].
9. Nuyten D.S., Kreike B., Hart A.A., et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006, 8(5):R62.
10. Driouch K., Landemaine T., Sin S., Wang S., Lidereau R. Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis. Clin Exp Metastasis 2007, 24(8):575-585.
11. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004, 40(18):2667-2675.
12. Anderson B.O., Yip C.H., Smith R.A., et al. Guideline implementation for breast healthcare in low- and middle income countries: overview of the breast health global initiative summit 2007. Cancer 2008, 113(8 Suppl.):2221-2242.
13. Eniu A., Carlson R.W., El Saghir N.S., et al. Guideline implementation for breast healthcare in low- and middle income countries: treatment resource allocation. Cancer 2008, 113(8 Suppl.):2268-2280.
14. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1869, 2:104-107.
15. Henderson M.D., Buroker T.R., Samson M.K., Mood D.W., Baker L.H., Vaitkevicius V.K. Response of patients with carcinoma of the breast to hormonal therapy and combination chemotherapy. Surg Gynecol Obstet 1975, 141(2 (August)):232-234.
16. Osborne C.K., Yochmowitz M.G., Knight W.A., McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980, 46(12 Suppl. (December)):2884-2888.
17. Ingle J.N. Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res 2004, 10(1 Pt. 2 (January)):362S-367S.
18. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27 (December)):2817-2826.
19. Blanco G., Holli K., Heikkinen M., Kallioniemi O.P., Taskinen P. Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 1990, 62:142-146.
20. Howell A., Robertson J.F., Vergote I. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res Treat 2003, 82(3 (December)):215-222.
21. Karlsson E., Lindström L.S., Wilking U., Skoog L., Johansson U., Bergh J. Discordance in hormone receptor status in breast cancer during tumor progression. Proc Am Soc Clin Oncol 2010, [Abstract 1009].
22. Amir E., Clemons M., Freedman O.C., et al. Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. Proc Am Soc Clin Oncol 2010, [Abstract 1007].
23. Locatelli M.A., Curigliano G., Fumagalli L., et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?. Proc Am Soc Clin Oncol 2010, [Abstract 1008].
24. Schroth W., Goetz M.P., Hamann U., et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302(13):1429-1436.
25. Goetz MP, Berry DA, Klein TE. Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the International Tamoxifen Pharmacogenomics Consortium. In: Proceedings of 32nd SABCS December 2009, San Antonio, TX [Abstract 33].
26. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97(1):30-39.
27. Buzdar A.U., Hortobagyi G.N. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 1998, 16(1 (January)):348-353.
28. Morris K.T., Toth-Fejel S., Schmidt J., Fletcher W.S., Pommier R.F. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. Surgery 2001, 30(6 (December)):947-953.
29. Bonneterre J., Thürlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000, 18(22 (November)):3748-3757.
30. Nabholtz J.M., Bonneterre J., Buzdar A., Robertson J.F., Thürlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003, 39(12 (August)):1684-1689.
31. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003, 21(11 (June)):2101-2109.
32. Kvinnsland S., Anker G., Dirix L.Y., et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000, 36(8 (May)):976-982.
33. Lønning P.E., Bajetta E., Murray R., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000, 8(11 (June)):2234-2244.
34. Chia S., Gradishar W., Mauriac L., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26(10 (April)):1664-1670.
35. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000, 8(7 (April)):1399-1411.
36. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998, 16(2 (February)):453-461.
37. Buzdar A., Douma J., Davidson N., et al. Phase III multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001, 19(14 (July)):3357-3366.
38. Miller W.R. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 1999, 6(2 (June)):187-195.
39. Goss PE, Ingle JN, Chapman J-AW, et al. Final analysis of NCIC CTG MA.27: a randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. In: Proceedings of 33rd SABCS, December 8-12, 2010, San Antonio, TX [Abstract S1-1].
40. Robertson J.F.R., Nicholson R.I., Bundred N.J., et al. Comparison of the short-term biological effects of 7alpha-[9-(4 4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001, 61:6739-6746.
41. Robertson JFR, Lindemann JPO, Llombart-Cussac A, et al. A comparison of fulvestrant 500mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the 'FIRST' study. In: Proceedings of 33rd SABCS, December 8-12, 2010, San Antonio, TX [Abstract S1-3].
42. Mauriac L., Romieu G., Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat 2009, 117(1):69-75.
43. Bergh J, Jönsson PE, Lidbrink E, et al. First results from FACT - an open-label, randomized phase III study investigating loading dose of fulvestrant combined with anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer. In: Proceedings of 32nd SABCS December 2009, San Antonio, TX [Abstract 23].
44. ATAC Trialists' Group Results of the ATAC (arimidex, tamoxifen alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
45. Stuart N.S., Warwick J., Blackledge G.R., et al. Study of tamoxifen vs. megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer 1996, 32A:1888-1892.
46. Lønning P.E., Taylor P.D., Anker G., et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001, 67:111-116.
47. Klijn J.G., Blamey R.W., Boccardo F., et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001, 19(2 (January)):343-353.
48. El-Saghir N.S., El-Hajj I.I., Makarem J.A., Otrock Z.K. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases. Anticancer Drugs 2006, 17(8 (September)):999-1002.
49. Carlson R.W., Theriault R., Shurman C.M., Rivera E., et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 2010, 28(25):3917-3921. Epub 2010 Aug 2.
50. Hudis C. Dose-dense chemotherapy for breast cancer: the story so far. Br J Cancer 2000, 82(12):1897-1899.
51. De Castro Junior G., Puglisi F., de Azambuja E., El Saghir N.S., Awada A. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol Hematol 2006, 59(1 (July)):40-50.
52. Hortobagyi G.N. Treatment of breast cancer. N Engl J Med 1998, 339(14 (October)):974-984.
53. Carlson R.W., Anderson B.O., Burstein H.J., et al. Invasive breast cancer. J Natl Compr Canc Netw 2007, 5(3 (March)):246-312.
54. Valero V., Holmes F.A., Walters R.S., et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995, 13(12 (December)):2886-2894.
55. Seidman A.D., Berry D., Cirrincione C., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008, 26(10 (April)):1642-1649.
56. Gonzalez-Angulo A.M., Hortobagyi G.N. Optimal schedule of paclitaxel: weekly is better. J Clin Oncol 2008, 26(10 (April)):1585-1587.
57. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23(31 (November)):7794-7803. [Epub 2005 September 19].
58. Thomas E.S., Gomez H.L., Li R.K., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007, 25(33):5210-5217.
59. Lechleider R.J., Kaminskas E., Jiang X., et al. Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. Clin Cancer Res 2008, 14(14):4378-4384.
60. http://www.cancer.gov/cancertopics/druginfo/fda-ixabepilone.
61. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/01/WC500062428.pdf.
62. Vahdat L.T., Pruitt B., Fabian C.J., et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009, 27(18):2954-2961.
63. Twelves C, Loesch D, Blum J, et al. Updated survival analysis of a phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in subjects with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. In: Proceedings of 33rd SABCS, December 8-12, 2010, San Antonio, TX [Abstract P6-14-18].
64. Awada A, Bondarenko IN, Tarasova O, et al. Results of the first randomized phase II study of cationin loposomal paclitaxel (EndoTAG TM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). In: Proceedings of the 2010 ESMO meeting, October 8-12, Milan, Italy [LBA 12].
65. Biganzoli L., Cufer T., Bruning P., et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002, 20(14 (July)):3114-3121.
66. Nabholtz J.M., Falkson C., Campos D., et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003, 21(6 (March)):968-975.
67. Bontenbal M., Creemers G.J., Braun H.J., et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005, 23(28 (October)):7081-7088.
68. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20(12 (June)):2812-2823.
69. Albain K.S., Nag S., Calderillo-Ruiz G., et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008, 26(24 (Aug)):3950-3957.
70. Martín M., Ruiz A., Muñoz M., et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007, 8(3 (March)):219-225.
71. Seidman A.D., Brufsky A., Ansari R.H., et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2009, [Abstract 1000].
72. Shamseddine A.I., Taher A., Dabaja B., Dandashi A., Salem Z., El Saghir N.S. Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer. Am J Clin Oncol 1999, 22(3 (June)):298-302.
73. Sirohi B., Arnedos M., Popat S., et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008, 19(11):1847-1852.
74. Liedtke C., Mazouni C., Hess K.R., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26(8):1275-1281.
75. Sparano J, Zhuang S, Londhe A, Lantz K, Lowery C. Relationship of anthracycline-free interval to outcomes in a phase 3 trial of pegylated liposomal doxorubicin plus docetaxel compared with docetaxel monotherapy in patients with advanced breast cancer treated with adjuvant anthracycline. In: Proceedings of 32nd SABCS, San Antonio, TX [Abstract 2095].
76. Swain S.M., Whaley F.S., Gerber M.C., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997, 15(4 (April)):1318-1332.
77. O'Brien M.E., Wigler N., Inbar M., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15(3 (March)):440-449.
78. Slamon D.J., Leyland-Jones B., Shak S., et al. Concurrent administration of anti-HER2 monoclonal antibody and first line chemotherapy for HER2 overexpressing metastatic breast cancer A phase III, multinational, randomized controlled trial. N Engl J Med 2001, 344:783-792.
79. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20(5 (March)):1215-1221.
80. Speyer J. Cardiac dysfunction in the trastuzumab clinical experience. J Clin Oncol 2002, 20(5 (March)):1156-1157.
81. Burstein H.J., Kuter I., Campos S.M., et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001, 19(10 (May)):2722-2730.
82. Pegram M., Forbes J., Pienkovski T., et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011, 29(2 (Jan)):149-156.
83. Blackwell K.L., Burstein H., O'Shaughnessy J., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28(7):1124-1130. Epub 2010 Feb 1.
84. Scheuer W., Friess T., Burtscher H., Bossenmaier B., Endl J., Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009, 69(24):9330-9336.
85. Hiroji I. Perspective of trastuzumab treatment initial treatment. Breast Cancer 2007, 14:150-155.
86. von Minckwitz G., du Bois A., Schmidt M., Maass N., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009, 27(12):1999-2006.
87. Swaby R., Blackwell K., Jiang Z., Sun Y., Dieras V., Zaman K. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. Proc Am Soc Clin Oncol 2009, [Abstract 1004].
88. Wood E.R., Truesdale A.T., Mc Donald O.B., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004, 64:6652-6659.
89. 2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002, 8:347-353.
90. Saez R., Molina M., Ramsey E., et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006, 12:424-431.
91. Scaltriti M., Rojo F., Ocaña A., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007, 99:628-638.
92. Xia W., Liu L.H., Ho P., et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004, 23:646-653.
93. Fujita T., Doihara H., Kawasaki K., et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006, 94:247-252.
94. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26 (December)):2733-2743.
95. Lin N.U., Carey L.A., Liu M.C., et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol 2008, 209120(April):1993-1999.
96. Fumoleau P, Wardley A, Miles D, et al. Safety of pertuzumab plus trastuzumab in a phase II trial of patients with HER2-overexpressing metastatic breast cancer which had progressed during trastuzumab therapy. In: Proceedings of 30th SABCS 2006, December 13-16, San Antonio, TX [Abstract 73].
97. Rabindran S.K., Discafani C.M., Rosfjord E.C., Baxter M., Floyd M.B., Golas J. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004, 64:3958-3965.
98. Krop I.E., Beeram M, Modi S., et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010, 28(16):2698-2704. Epub 2010 Apr 26.
99. Burris H.A., Rugo H.S., O'Shaughnessy J.A., et al. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy. J Clin Oncol 2011, 29(4):398-405. Epub 2010 Dec 20.
100. Miller K., Gianni L., Andre F., et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). Proc Am Soc Clin Oncol 2010, [Abstract 1012].
101. Modi S., Stopeck A.T., Gordon M.S., et al. Combination of trastuzumab and tanespimycin (17-AAG KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007, 25(34 (December)):5410-5417.
102. Kaufman B., Mackey J.R., Clemens M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27(33):5529-5537.
103. Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27(33):5538-5546.
104. Ro J, Pippen J, Pivot X, et al. Safety of first-line letrozole compared with lapatinib plus letrozole in patients with postmenopausal hormone receptor positive metastatic breast cancer: EGF30008 study. In: Proceedings of 32nd SABCS, San Antonio, TX [Abstract 5094].
105. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
106. Miller K.D. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003, 3(6 (February)):421-422.
107. Miles DW, Chan A, Romieu G, et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). In: Proceedings of 32nd SABCS 2009, San Antonio, TX [Abstract 41].
108. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2009, [Abstract 1005].
109. O'Shaughnessy J., Miles D., Gray R.J., et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2010, [Abstract 1005].
110. Brufsky A, Bondarenko IN, Smirnov V, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. In: Proceedings of 32nd SABCS, San Antonio, TX [Abstract 42].
111. http://www.cancer.org/Cancer/news/News/fda-advisory-panel-votes-against-avastin-for-advanced-breast-cancer.
112. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237172.htm.
113. Smerdel M.P., Steffenson K.D., Waldstrom M., Brandslund I., Jakodsen A. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010, 118(2 (August)):167-171.
114. Choueiri T.K. Axitinib a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 2008, 9(6 (June)):658-671.
115. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26(11 (April)):1810-1816.
116. Barrios C, Liu M-C, Lee SC, et al. Phase III randomized trial of sunitinib (SU) vs. capecitabine (C) in patients (Pts) with previously treated HER2-negative advanced breast cancer (ABC). Proceedings of 32nd SABCS 2009, San Antonio, TX [Abstract 46].
117. Bergh J., Greil R., Voytko N., et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). Proc Am Soc Clin Oncol 2010, [Abstract LBA 1010].
118. Crown J., Dieras V., Staroslawska E., et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). Proc Am Soc Clin Oncol 2010, [Abstract LBA 1011].
119. Baselga J, Grupo Español de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos, Roché H, et al. SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). In: Proceedings of 32nd SABCS 2009, San Antonio, TX [Abstract 45].
120. Tutt A., Robson M., Carmicheal J., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376(9737):235-244. Epub 2010 Jul 6.
121. O'Shaughnessy J., Osborne C., Pippen J.E., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. New Engl J Med 2011, 364(3):205-214.
122. Baselga J, Gomez P, Awada A, et al. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1). In: Proceedings of the 2010 ESMO meeting, October 8-12, Milan, Italy [Abstract 2740].
123. Hortobagyi G.N., Theriault R.L., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996, 335:1785-1791.
124. Coleman R., Burkinshaw R., Brown J., et al. Zoledronic acid. Expert Opin Drug Saf 2011, 10(1):133-145. Epub 2010 Nov 29.
125. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
126. Lipton A., Steger G.G., Figueroa J., et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008, 14(20 (October)):6690-6696.
127. Stopeck A.T., Lipton A., Braun A., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28(35):5132-5139. Epub 2010 Nov 8.
128. Lin N.U., Bellon J.R., Winer E.P. CNS metastases in breast cancer. J Clin Oncol 2004, 22(17 (September)):3608-3617.
129. Khan S.A., Stewart A.K., Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer?. Surgery 2002, 132(4 (October)):620-626. [discussion 626-7].
130. Rapiti E., Verkooijen H.M., Vlastos G., et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006, 24(18 (June)):2743-2749.
131. Babiera G.V., Rao R., Feng L., et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006, 13(6):776-782.
132. Korkaya H., Wicha M.S. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 2007, 21(5):299-310.
133. El Saghir N.S., Eniu A., Carlson R.W., Aziz Z., Vorobiof D., Hortobagyi G.N. Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries. Cancer 2008, 113(8 Suppl. (October)):2315-2324.